CD274 and cancer: CRISPR/Cas9 knockout technology can irreversibly inhibit the PD-L1 immune checkpoint, awakening immunosuppressed T cells from differentiating into cytotoxic T lymphocytes, thus triggering a series of robust immune responses to suppress cancer cells (Fig. 8G).